Adolescent Cannabis Use & Psychotic Disorders Study: Factsheet & FAQs

This is one of the largest and strongest studies to date linking adolescent cannabis use to the risk of developing serious psychiatric disorders

This longitudinal study followed nearly half a million adolescents (463,396) who were screened during standard pediatric care for cannabis use and tracked through young adulthood. It found that any past-year cannabis use during adolescence was associated with a significantly increased risk of developing clinically diagnosed psychotic, bipolar, depressive, and anxiety disorders by age 26. The size, diversity, and real-world design of this study set it apart from much of the prior research on this issue.

Why it matters:  This moves the evidence beyond small samples, self-reported symptoms, or cannabis use disorder alone into a population-level sample, which includes physician-diagnosed mental illness.

The strongest risks were for the most severe outcomes: psychosis and bipolar disorder

The study found the largest and most concerning associations for psychotic and bipolar disorders, with adolescent cannabis use linked to:

• More than double the risk of psychotic disorders
• Roughly double the risk of bipolar disorder by early adulthood

These findings are consistent with and add to previous research showing that cannabis use in adolescence is a risk factor for developing psychiatric conditions.

Why it matters: These are not mild or transient effects; psychotic and bipolar disorders are life-altering conditions with long-term consequences for health, education, employment, and family stability.

Adolescence is a uniquely vulnerable window for cannabis-related mental health harm

The study shows that associations with depressive and anxiety disorders were strongest when cannabis use occurred during earlier adolescence, a critical period of brain development. Risks for depression and anxiety diminished as individuals aged, reinforcing the conclusion that early exposure matters most.

This is biologically plausible: THC acts on CB1 receptors, which are highly expressed in the adolescent brain and play a key role in emotional regulation, motivation, and cognitive development.

Why it matters: Policies that delay initiation—even if they don’t eliminate adult use—can meaningfully reduce psychiatric harm.

These risks were observed even with “any past-year use”—not just heavy or daily use

Importantly, the study did not require daily use, high frequency, or a cannabis use disorder diagnosis. Any self-reported past-year cannabis use was associated with elevated psychiatric risk. This is particularly striking given today’s cannabis landscape, where typical THC levels exceed 20%, far higher than in past decades.

Why it matters: This undercuts the common narrative that cannabis is only risky for “heavy users” and highlights the dangers of widespread normalization, especially for youth.

The findings strongly suggest that cannabis use in adolescence is a risk factor for developing psychiatric conditions

• Cannabis use preceded psychiatric diagnoses by 1.7–2.3 years on average
• Results held after adjusting for prior mental health conditions and other substance use
• Sensitivity analyses excluding youth with any psychiatric history still showed elevated risk

Why it matters: This challenges industry-friendly narratives that cannabis use among youth is merely a response to pre-existing psychiatric conditions.

The study highlights growing health equity concerns in legal cannabis markets

Cannabis use was more common among:

• Older adolescents
• Black, Hispanic, and White youth
• Youth on Medicaid or living in more deprived neighborhoods

These patterns mirror broader inequities in marketing exposure, retail density, and enforcement and raise serious concerns about disparate mental health impacts as cannabis becomes more commercialized.

Why it matters: Weak youth protections risk amplifying—not reducing—mental health disparities

The findings make a clear case for prevention-focused cannabis policy, not laissez-faire legalization

This study reinforces the need for:

• Early screening and prevention in pediatric care
• Stronger limits on youth access, marketing, and exposure
• Clear, prominent mental health warnings
• Restrictions on product potency, packaging, flavors, and advertising
• Targeted prevention and mental health support for youth

As cannabis becomes more accessible and socially accepted, policy choices—not inevitability—will determine youth mental health outcomes.

Why it matters: These research findings call out for a public health approach that prioritizes prevention and guardrails to protect youth over profit and normalization.

Frequently Asked Questions

Q: Does this study prove cannabis causes mental illness?
A: While causation can’t be definitively established, cannabis use was associated with an increased risk of developing psychiatric conditions, and the associations remained strong after adjusting for confounders.

Of note, the study had the power to assess associations with the incidence of severe but less common outcomes of bipolar and psychiatric conditions.

Q: Is this only about heavy or daily cannabis use?
A: No. The study examined any past-year cannabis use, not just heavy use or cannabis use disorder. Elevated risks were observed even at this broader level of exposure.

Q: Why are psychosis and bipolar disorder especially concerning?
A: Schizophrenia and other psychotic disorders and bipolar disorder are severe, often lifelong conditions which can profoundly disrupt the lives of those affected and their families. The study found the strongest associations for these two disorders, reinforcing concerns that adolescent cannabis use may increase risk for the most serious psychiatric conditions.

Q: Could teens be using cannabis to self-medicate early mental health symptoms?
A: That is possible in some cases, but this study adjusted for prior mental health history and still found increased risk. Cannabis use preceded diagnoses by 1.7 to 2.3 years on average, suggesting it is not simply a consequence of pre-existing illness. However, it is possible that teens were self-medicating early mental health symptoms that did not come to the attention of the healthcare system.

Q: How does THC potency factor in?
A: Today’s cannabis products are far more potent than in the past. Increased cannabis potency has been associated with higher risk of psychosis and of problem use. THC interacts with brain systems that are still developing during adolescence.

Q: Should parents and pediatricians be concerned?
A: Yes. The study highlights the importance of routine screening, early conversations, and prevention during adolescence, when the brain is most vulnerable.